Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

953 - A Phase I first-in-human, dose-escalation and expansion study to evaluate the safety and tolerability of NUC-3373 in patients with locally advanced, unresectable or metastatic solid malignancies

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Clinical Research

Tumour Site

Presenters

Sarah Blagden

Citation

Annals of Oncology (2018) 29 (suppl_8): viii133-viii148. 10.1093/annonc/mdy279

Authors

S. Blagden1, P. Spiliopoulou2, L. Spiers1, C. Gnanaranjan3, C. Qi4, V.K. Woodcock1, J. Moschandreas4, H.E.J. Tyrrell1, L. Griffiths5, C. Butcher5, E. Ghazaly3, T.R..J. Evans2

Author affiliations

  • 1 Department Of Oncology, Churchill Hospital University of Oxford, OX3 7LE - Oxford/GB
  • 2 Institute Of Cancer Sciences, Beatson Institute for Cancer Research, G61 1BD - Glasgow/GB
  • 3 Centre For Haemato-oncology, Barts Cancer Centre, EC1M6BQ - London/GB
  • 4 Nuffield Department Of Orthopaedics, Rheumatology And Musculoskeletal Sciences, Centre for Statistics in Medicine, OX37LD - Oxford/GB
  • 5 Oncology Clinical Trials Office, University of Oxford, OX37LE - Oxford/GB

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 953

Background

The anti-cancer activity of 5-FU, and its other forms: floxuridine and capecitabine, is largely attributable to its active metabolite, fluorodeoxyuridine-monophosphate (FUDR-MP) that inhibits the enzyme thymidylate synthase (TS) and depletes the dTMP pool essential for cancer cell replication. Although 5-FU based agents remain the cornerstone of treatment for many tumour types, key cellular resistance mechanisms of breakdown, activation and transport limit their effectiveness. NUC-3373 is a phosphoramidate transformation of FUDR-MP designed to bypass these resistance pathways. It efficiently inhibits TS and depletes the dTMP pool within 2-4 hours. NUC-3373 is resistant to dihydropyrimidine dehydrogenase-mediated degradation and does not generate the toxic metabolite dhFU. NUC3373 has an advantageous PK/PD profile compared to 5-FU, with plasma t1/2=9.7 h vs 8-14 mins, enabling the study of a more convenient alternate weekly dose-scheduling (Ghazaly et al ESMO, 2017).

Trial design

The primary study objective is to determine the RP2D and schedule of NUC3373 in patients with advanced cancers. Secondary objectives include safety, anti‐tumour activity and PK/PD. In Part I, NUC‐3373 was administered as an IV infusion on days 1, 8, 15 and 22 of a 28‐day cycle. In Part II, NUC-3373 was administered on days 1 and 15 of a 28‐day cycle. For PK analyses, blood samples were collected at 12 timepoints up to 48 h post‐dose during cycle 1. Plasma and intracellular metabolites were measured by UPLC-MS/MS. Levels of free and bound TS were measured in PBMCs by western blotting. To date, thirty-six patients have been enrolled: Part I n = 29; Part II n = 7. Dose escalation is ongoing to establish the RP2D. Cohorts in Part I received NUC-3373 at 125, 250, 500, 750, 1125 and 1500 mg/m2 and cohorts in Part II at 1500 and 1875 mg/m2.

Clinical trial identification

NCT02723240.

Legal entity responsible for the study

Nucana plc.

Funding

Nucana plc.

Editorial Acknowledgement

Disclosure

S. Blagden: Advisor: Ellipses, Director of RNA Guardian Ltd.; Advisory boards: Clovis and Novartis; Research funding Nucana plc (unrelated to NUC-3373). T.R.J. Evans: Institution receives financial support for the costs of conducting this clinical trial and other studies with another of Nucana's compounds. Institution has also been reimbursed for time in a one-off advisory board for Nucana for another of their compounds. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.